ASND
Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology · DK
$270.56
−0.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 691.7M | 363.6M | 266.7M | 51.2M |
| Cost of Revenue | 103.5M | 103.2M | 44.3M | 44.4M | 12.1M |
| Gross Profit | 950.9M | 588.5M | 319.4M | 222.3M | 39.0M |
| Operating Expenses | |||||
| R&D Expense | 274.1M | 283.5M | 307.0M | 413.5M | 379.6M |
| SG&A Expense | 565.6M | 435.9M | 284.5M | 258.8M | 215.8M |
| General & Admin Expense | 111.7M | — | 284.5M | 258.8M | 215.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.7M | — | 6.6M | 5.6M | 5.4M |
| Total Operating Expenses | 841.4M | 719.4M | 598.1M | 677.9M | 600.9M |
| Cost and Expenses | 944.9M | 822.6M | 642.4M | 722.3M | 613.0M |
| Operating Income (EBIT) | 109.5M | (130.9M) | (278.8M) | (455.5M) | (561.8M) |
| Non-Operating | |||||
| Interest Income | 52.0M | 14.7M | 14.4M | 16.9M | 7.4M |
| Interest Expense | 163.9M | 77.5M | 65.5M | 44.1M | 30.7M |
| Net Interest Income | (111.9M) | (62.8M) | (51.1M) | (27.2M) | (23.3M) |
| Other Non-Op Income/Expense | (8.3M) | (73.4M) | (94.5M) | (18.6M) | (16.0M) |
| Non-Operating Income (excl Interest) | 49.1M | (4.1M) | 29.0M | (25.5M) | (14.7M) |
| EBT (Pre-Tax Income) | 101.1M | (204.3M) | (373.2M) | (474.1M) | (577.8M) |
| Income Tax Expense | (654.7M) | 14.8M | 4.8M | 7.3M | 5.4M |
| Bottom Line | |||||
| Net Income | 755.8M | (219.0M) | (378.1M) | (481.4M) | (583.2M) |
| Earnings from Cont. Ops | 755.8M | (219.0M) | (378.1M) | (481.4M) | (583.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 755.8M | (219.0M) | (378.1M) | (481.4M) | (583.2M) |
| Per Share | |||||
| Basic EPS | $12.10 | ($3.62) | ($6.53) | ($8.55) | ($10.40) |
| Diluted EPS | $11.45 | ($3.62) | ($6.53) | ($8.55) | ($10.40) |
| Revenue Per Share | $16.39 | $11.41 | $6.28 | $4.74 | $0.91 |
| Shares | |||||
| Basic Shares Outstanding | 64.3M | 60.6M | 57.9M | 56.3M | 56.1M |
| Diluted Shares Outstanding | 68.3M | 60.6M | 57.9M | 56.3M | 56.1M |
| Profitability Metrics | |||||
| EBITDA | 78.1M | (109.8M) | (290.0M) | (411.2M) | (529.2M) |
| D&A | 17.7M | 17.0M | 17.7M | 18.9M | 17.5M |
| EBIT | 60.4M | (126.8M) | (307.7M) | (430.1M) | (547.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026